BP
TMO icon

Ballentine Partners’s Thermo Fisher Scientific TMO Stock Holding History

Ballentine Partners’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Sell
7,469
-41
-0.5% -$19.7K 0.05% 135
2026
Q1 		$3.69M Sell
7,510
-152
-2% -$82.5K 0.05% 124
2025
Q4 		$4.44M Buy
7,662
+136
+2% +$76.9K 0.06% 105
2025
Q3 		$3.65M Buy
7,526
+836
+12% +$389K 0.05% 120
2025
Q2 		$2.71M Sell
6,690
-619
-8% -$259K 0.04% 152
2025
Q1 		$3.64M Sell
7,309
-147
-2% -$79.6K 0.06% 109
2024
Q4 		$3.88M Sell
7,456
-804
-10% -$442K 0.07% 100
2024
Q3 		$5.11M Buy
8,260
+543
+7% +$321K 0.09% 83
2024
Q2 		$4.27M Sell
7,717
-86
-1% -$49.3K 0.08% 88
2024
Q1 		$4.54M Buy
7,803
+864
+12% +$485K 0.09% 81
2023
Q4 		$3.68M Sell
6,939
-1,950
-22% -$944K 0.08% 93
2023
Q3 		$4.5M Buy
8,889
+1,733
+24% +$923K 0.11% 75
2023
Q2 		$3.73M Buy
7,156
+295
+4% +$159K 0.09% 82
2023
Q1 		$3.95M Buy
6,861
+225
+3% +$127K 0.1% 80
2022
Q4 		$3.65M Buy
6,636
+573
+9% +$304K 0.11% 73
2022
Q3 		$3.08M Buy
6,063
+582
+11% +$326K 0.11% 74
2022
Q2 		$2.98M Buy
5,481
+158
+3% +$87K 0.11% 72
2022
Q1 		$3.14M Buy
5,323
+52
+1% +$29.9K 0.1% 77
2021
Q4 		$3.52M Buy
5,271
+334
+7% +$209K 0.11% 75
2021
Q3 		$2.82M Buy
4,937
+19
+0.4% +$10.4K 0.1% 79
2021
Q2 		$2.48M Buy
4,918
+110
+2% +$51.9K 0.09% 80
2021
Q1 		$2.19M Buy
4,808
+181
+4% +$86.4K 0.08% 87
2020
Q4 		$2.16M Sell
4,627
-557
-11% -$261K 0.09% 82
2020
Q3 		$2.29M Sell
5,184
-101
-2% -$41.7K 0.1% 76
2020
Q2 		$1.91M Sell
5,285
-528
-9% -$177K 0.09% 87
2020
Q1 		$1.65M Buy
5,813
+62
+1% +$19.6K 0.1% 87
2019
Q4 		$1.87M Sell
5,751
-30
-0.5% -$9.1K 0.08% 97
2019
Q3 		$1.68M Sell
5,781
-88
-1% -$25.2K 0.08% 104
2019
Q2 		$1.72M Buy
5,869
+623
+12% +$172K 0.08% 100
2019
Q1 		$1.44M Buy
5,246
+60
+1% +$14.9K 0.07% 96
2018
Q4 		$1.16M Sell
5,186
-101
-2% -$23.7K 0.07% 103
2018
Q3 		$1.29M Buy
5,287
+355
+7% +$81.7K 0.07% 107
2018
Q2 		$1.02M Buy
4,932
+289
+6% +$61.3K 0.06% 117
2018
Q1 		$959K Buy
4,643
+93
+2% +$19.5K 0.05% 116
2017
Q4 		$864K Buy
4,550
+119
+3% +$22.8K 0.05% 136
2017
Q3 		$838K Sell
4,431
-41
-0.9% -$7.42K 0.05% 144
2017
Q2 		$801K Sell
4,472
-154
-3% -$25.9K 0.06% 147
2017
Q1 		$711K Sell
4,626
-143
-3% -$21.9K 0.05% 95
2016
Q4 		$673K Buy
4,769
+554
+13% +$81.7K 0.05% 87
2016
Q3 		$671K Sell
4,215
-129
-3% -$19.9K 0.05% 78
2016
Q2 		$643K Buy
4,344
+16
+0.4% +$2.36K 0.05% 90
2016
Q1 		$613K Buy
4,328
+282
+7% +$37.8K 0.05% 94
2015
Q4 		$574K Buy
4,046
+60
+2% +$8K 0.06% 86
2015
Q3 		$488K Buy
3,986
+7
+0.2% +$912 0.05% 90
2015
Q2 		$516K Buy
3,979
+18
+0.5% +$2.35K 0.05% 87
2015
Q1 		$532K Sell
3,961
-43
-1% -$5.54K 0.05% 84
2014
Q4 		$502K Buy
+4,004
New +$487K 0.06% 86

Other funds holding TMO

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LT
Lindsell Train London, United Kingdom $2.63B AUM 2.97% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CF
Canoe Financial Calgary, Alberta, Canada $8.07B AUM 25.47% 1-Year Est. Return
SP
Sarasin & Partners London, United Kingdom $8.54B AUM 9.6% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

Ballentine Partners's TMO Position: Q2 2026 in Review

Ballentine Partners reduced its Thermo Fisher Scientific (TMO) stake by 0.55% in Q2 2026, selling an estimated $19.7K and leaving 7,469 shares worth $3.74M. The position accounts for 0.05% of the portfolio, ranked #135.

Ballentine Partners first reported a position in TMO in Q4 2014 and has held it in 47 quarters since. The position peaked at $5.11M in Q3 2024. 429 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Ballentine Partners held 7,469 shares of Thermo Fisher Scientific worth $3.74M as of Q2 2026.
  • Ballentine Partners sold 41 Thermo Fisher Scientific shares in Q2 2026, an estimated $19.7K.
  • Thermo Fisher Scientific made up 0.05% of Ballentine Partners's portfolio in Q2 2026, its #135 holding.
  • Ballentine Partners first reported a position in Thermo Fisher Scientific in Q4 2014 and has held it in 47 quarters since.
  • Ballentine Partners's Thermo Fisher Scientific position peaked at $5.11M in Q3 2024.
  • 429 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.